NEW YORK, July 13, 2017 /PRNewswire/ --
If you want a Stock Review on NVRO, ETRM, AVGR, or VRAY then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. For today, DailyStockTracker.com shifts focus on Nevro Corp. (NYSE: NVRO), EnteroMedics Inc. (NASDAQ: ETRM), Avinger Inc. (NASDAQ: AVGR), and ViewRay Inc. (NASDAQ: VRAY). Medical Appliances and Equipment companies are engaged in the manufacture of medical instruments. They also tend to offer below-average dividend yields when compared to the wider market. These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at:
http://dailystocktracker.com/register/
Nevro
Redwood City, California headquartered Nevro Corp.'s stock finished Wednesday's session 2.09% higher at $84.07 with a total trading volume of 509,158 shares. Over the last month and since the start of this year, the Company's shares have advanced 18.03% and 15.70%, respectively. The stock is trading above its 50-day moving average by 9.88%. Moreover, shares of Nevro, which focuses on providing products for the patients suffering from chronic pain in the US and internationally, have a Relative Strength Index (RSI) of 66.57.
On July 05th, 2017, Nevro announced that preliminary unaudited worldwide revenue for the Q2 ended June 30th, 2017 is expected to be in the range of $77.5 to $78.0 million compared to $55.4 million in Q2 2016. Preliminary unaudited US revenue for Q2 2017 is expected to be in the range of $62.7 million to $63.0 million. Additionally, preliminary unaudited international revenue for the quarter is expected to be in the range of $14.8 million to $15.0 million. Your complete research report on NVRO can be retrieved for free at:
http://dailystocktracker.com/registration/?symbol=NVRO
EnteroMedics
Shares in St. Paul, Minnesota headquartered EnteroMedics Inc. declined 1.78%, ending yesterday's session at $4.42 with a total trading volume of 96,228 shares. The stock has gained surged 121.00% on an YTD basis. The Company's shares are trading 8.56% below their 50-day moving average. Moreover, shares of EnteroMedics, which focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, have an RSI of 35.43.
On June 28th, 2017, EnteroMedics announced the launch of the vBloc Now program. The program provides qualified patients access to vBloc® Therapy at a reduced cost, in partnership with select bariatric and weight loss centers across the US. vBloc Therapy is designed to help patients feel full, eat less food, and lose weight, thereby improving their overall health. A free report on ETRM is just a click away at:
http://dailystocktracker.com/registration/?symbol=ETRM
Avinger
On Wednesday, Redwood City, California headquartered Avinger Inc.'s stock saw a decline of 4.07%, to close the day at $0.44. A total volume of 1.13 million shares was traded. The Company's shares have advanced 14.57% in the last one month. The stock is trading 0.65% below its 50-day moving average. Additionally, shares of Avinger, which designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease in the US and Europe, have an RSI of 49.03. Sign up for your complimentary research report on AVGR at:
http://dailystocktracker.com/registration/?symbol=AVGR
ViewRay
Shares in Bedford, Ohio headquartered ViewRay Inc. ended the day 2.08% lower at $6.58. A total volume of 421,189 shares was traded. The stock has gained 6.65% in the last one month and 110.22% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 2.10% and 26.53%, respectively. Furthermore, shares of ViewRay, which through its subsidiary, ViewRay Technologies, Inc., designs, manufactures, and markets radiation therapy systems, have an RSI of 52.70.
On June 26th, 2017, ViewRay announced that the National Cancer Center (NCC) in Tokyo, Japan treated its first patients using the former's MRIdian System, the world's first and only clinical MRI-guided radiation therapy system. Among the first indications treated at NCC were cancers of the lung, liver, and pancreas. The MRIdian System combines MR imaging with radiation delivery so clinicians can visualize soft tissue and adjust their dosing - all in real time on live anatomy.
On June 30th, 2017, research firm Cantor Fitzgerald initiated an 'Overweight' rating on the Company's stock, with a target price of $10 per share. Register for free on DailyStockTracker.com and download the latest research report on VRAY at:
http://dailystocktracker.com/registration/?symbol=VRAY
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Advertisement
If you want a Stock Review on NVRO, ETRM, AVGR, or VRAY then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. For today, DailyStockTracker.com shifts focus on Nevro Corp. (NYSE: NVRO), EnteroMedics Inc. (NASDAQ: ETRM), Avinger Inc. (NASDAQ: AVGR), and ViewRay Inc. (NASDAQ: VRAY). Medical Appliances and Equipment companies are engaged in the manufacture of medical instruments. They also tend to offer below-average dividend yields when compared to the wider market. These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at:
Advertisement
http://dailystocktracker.com/register/
Nevro
Redwood City, California headquartered Nevro Corp.'s stock finished Wednesday's session 2.09% higher at $84.07 with a total trading volume of 509,158 shares. Over the last month and since the start of this year, the Company's shares have advanced 18.03% and 15.70%, respectively. The stock is trading above its 50-day moving average by 9.88%. Moreover, shares of Nevro, which focuses on providing products for the patients suffering from chronic pain in the US and internationally, have a Relative Strength Index (RSI) of 66.57.
On July 05th, 2017, Nevro announced that preliminary unaudited worldwide revenue for the Q2 ended June 30th, 2017 is expected to be in the range of $77.5 to $78.0 million compared to $55.4 million in Q2 2016. Preliminary unaudited US revenue for Q2 2017 is expected to be in the range of $62.7 million to $63.0 million. Additionally, preliminary unaudited international revenue for the quarter is expected to be in the range of $14.8 million to $15.0 million. Your complete research report on NVRO can be retrieved for free at:
http://dailystocktracker.com/registration/?symbol=NVRO
EnteroMedics
Shares in St. Paul, Minnesota headquartered EnteroMedics Inc. declined 1.78%, ending yesterday's session at $4.42 with a total trading volume of 96,228 shares. The stock has gained surged 121.00% on an YTD basis. The Company's shares are trading 8.56% below their 50-day moving average. Moreover, shares of EnteroMedics, which focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders, have an RSI of 35.43.
On June 28th, 2017, EnteroMedics announced the launch of the vBloc Now program. The program provides qualified patients access to vBloc® Therapy at a reduced cost, in partnership with select bariatric and weight loss centers across the US. vBloc Therapy is designed to help patients feel full, eat less food, and lose weight, thereby improving their overall health. A free report on ETRM is just a click away at:
http://dailystocktracker.com/registration/?symbol=ETRM
Avinger
On Wednesday, Redwood City, California headquartered Avinger Inc.'s stock saw a decline of 4.07%, to close the day at $0.44. A total volume of 1.13 million shares was traded. The Company's shares have advanced 14.57% in the last one month. The stock is trading 0.65% below its 50-day moving average. Additionally, shares of Avinger, which designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease in the US and Europe, have an RSI of 49.03. Sign up for your complimentary research report on AVGR at:
http://dailystocktracker.com/registration/?symbol=AVGR
ViewRay
Shares in Bedford, Ohio headquartered ViewRay Inc. ended the day 2.08% lower at $6.58. A total volume of 421,189 shares was traded. The stock has gained 6.65% in the last one month and 110.22% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 2.10% and 26.53%, respectively. Furthermore, shares of ViewRay, which through its subsidiary, ViewRay Technologies, Inc., designs, manufactures, and markets radiation therapy systems, have an RSI of 52.70.
On June 26th, 2017, ViewRay announced that the National Cancer Center (NCC) in Tokyo, Japan treated its first patients using the former's MRIdian System, the world's first and only clinical MRI-guided radiation therapy system. Among the first indications treated at NCC were cancers of the lung, liver, and pancreas. The MRIdian System combines MR imaging with radiation delivery so clinicians can visualize soft tissue and adjust their dosing - all in real time on live anatomy.
On June 30th, 2017, research firm Cantor Fitzgerald initiated an 'Overweight' rating on the Company's stock, with a target price of $10 per share. Register for free on DailyStockTracker.com and download the latest research report on VRAY at:
http://dailystocktracker.com/registration/?symbol=VRAY
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
